Product Description
Recombinant von Willebrand Factor / vWF Antibody [VWF/1859R] | 33-835 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: Amino acids 1815-1939 from the human protein were used as the immunogen for this recombinant vWF antibody.
Research Area: Cancer, Stem Cell
Tested Application: WB, IF, IHC-P
Application: Western blot: 1-2 ug/ml
Immunoprecipitation: 1-2ug/500ug lysate
Immunofluorescence: 1-2 ug/ml
Immunohistochemistry (FFPE) : 1-2 ug/ml for 30 minutes at RT
The optimal dilution of the recombinant vWF antibody for each application should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein A affinity chromatography
Clonality: Recombinant Monoclonal
Clone: VWF/1859R
Isotype: IgG, k
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: VWF, Coagulation factor VIII VWF, F8VWF, VWD, Von Willebrand factor
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.